Baker Bros. Advisors’s Trillium Therapeutics Inc. TRIL Stock Holding History

Baker Bros. Advisors’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,100,000	Closed	-$1.13M	–	115
2019 Q4	$1.13M	Buy	1,100,000 +594,738	+118%	+$227K	0.01%	92
2019 Q3	$155K	Hold	505,262	–	–	﹤0.01%	108
2019 Q2	$166K	Hold	505,262	–	–	﹤0.01%	103
2019 Q1	$333K	Hold	505,262	–	–	﹤0.01%	95
2018 Q4	$864K	Hold	505,262	–	–	0.01%	84
2018 Q3	$2.93M	Sell	505,262 -6,501	-1%	-$36.6K	0.02%	84
2018 Q2	$3.07M	Buy	511,763 +102,440	+25%	+$653K	0.02%	91
2018 Q1	$2.95M	Hold	409,323	–	–	0.03%	86
2017 Q4	$2.97M	Sell	409,323 -4,374	-1%	-$36.2K	0.03%	90
2017 Q3	$2.13M	Hold	413,697	–	–	0.02%	97
2017 Q2	$1.82M	Hold	413,697	–	–	0.02%	89
2017 Q1	$2.54M	Hold	413,697	–	–	0.02%	82
2016 Q4	$2.34M	Hold	413,697	–	–	0.02%	88
2016 Q3	$6.12M	Buy	413,697 +201,905	+95%	+$2.32M	0.06%	64
2016 Q2	$1.9M	Hold	211,792	–	–	0.02%	99
2016 Q1	$1.96M	Hold	211,792	–	–	0.02%	100
2015 Q4	$2.67M	Buy	211,792 +148,778	+236%	+$2.07M	0.02%	100
2015 Q3	$821K	Buy	+63,014	New	+$1.16M	0.01%	122

Other funds holding TRIL

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Baker Bros. Advisors's TRIL Position: Q1 2020 in Review

Baker Bros. Advisors sold out of Trillium Therapeutics Inc. (TRIL) in Q1 2020, closing a stake of 1,100,000 shares — an estimated $1.13M sold.

Baker Bros. Advisors first reported a position in TRIL in Q3 2015 and held it in 18 quarters. The position peaked at $6.12M in Q3 2016. 65 funds tracked by Wall St. Rank hold TRIL as of Q1 2020.

Baker Bros. Advisors reported no remaining Trillium Therapeutics Inc. position as of Q1 2020 after selling out during the quarter.
Baker Bros. Advisors sold 1,100,000 Trillium Therapeutics Inc. shares in Q1 2020, an estimated $1.13M.
Baker Bros. Advisors first reported a position in Trillium Therapeutics Inc. in Q3 2015 and held it in 18 quarters.
Baker Bros. Advisors's Trillium Therapeutics Inc. position peaked at $6.12M in Q3 2016.
65 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q1 2020.

Based on Baker Bros. Advisors's 13F filing for Q1 2020, filed 15 May 2020.